Tarsus Pharmaceuticals, Inc..
TARS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address prevalent diseases. Their lead product candidate, TP-03, is designed for the treatment of Demodex blepharitis, an ocular disease caused by Demodex mite in...Show More
Better Health for All
-10
Tarsus Pharmaceuticals' core business is dedicated to developing therapeutic candidates for prevalent diseases. Its lead product, XDEMVY, is an FDA-approved treatment for Demodex blepharitis,
1
a condition affecting 58% of eye care patients in the US,
2
with 80% reporting negative impacts on daily activities.
3
The company is also developing TP-05 for Lyme disease prevention,
4
which showed statistically significant tick mortality in Phase 2a trials,
5
and TP-04 for Ocular Rosacea.
6
These efforts demonstrate a strong commitment to health improvement and addressing unmet medical needs. Regarding safety, XDEMVY showed no serious treatment-related adverse events in over 800 patients.
7
The most common side effects were instillation site stinging and burning (10%),
8
with chalazion/hordeolum (stye) and punctate keratitis occurring in less than 2% of patients.
9
For price accessibility, Tarsus offers the Tarsus Connect financial support program,
10
aiming for patients to pay as little as $30,
11
with over 85% insurance coverage for Commercial, Medicare Part D, and Medicaid patients.
12
However, the gross-to-net discount for XDEMVY was in the low 40s in Q3 2024.
13
The company provides full prescribing information for XDEMVY on its website,
14
but specific details on risk transparency beyond this are not provided. Tarsus holds patent exclusivity for TP-04 until 2038,
15
with no information on patent flexibility for other products.
Fair Money & Economic Opportunity
0
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic candidates.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers, which is the primary focus of the 'Fair Money & Economic Opportunity' value.
2
Therefore, the company does not offer consumer credit products, manage customer financial data, or engage in financial services activities that would allow for scoring against the quantitative thresholds for most KPIs in this rubric.
3
While the company offers a Patient Assistance Program for its medication XDEMVY to eligible patients with limited or no prescription insurance coverage, and focuses on diseases with high unmet needs, these initiatives are related to healthcare access and affordability, not financial services or economic opportunity as defined by the rubric's KPIs.
4
Fair Pay & Worker Respect
10
In 2024, the CEO's total compensation was 37 times the median employee compensation.
1
Employee sentiment data indicates that 79% of employees would recommend working at the company to a friend, and 88% approve of the CEO.
2
Multiple articles state that no regulatory actions, violations, fines, or compliance issues related to labor laws are mentioned.
3
The company offers employer-provided health, dental, vision, life, disability, FSA, HSA, and mental health insurance, as well as paid time off and parental leave, but the percentage of the workforce covered by these benefits is not specified.
4
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, share of high-risk materials, or supplier diversity spend was found in the provided articles.
1
Both articles explicitly state that data related to these fair trade and ethical sourcing metrics is not applicable or not included.
2
Honest & Fair Business
-30
The company has a formal whistleblower policy with anonymous reporting channels, including a hotline and online portal.
1
The Audit Committee is responsible for establishing and overseeing procedures for handling these complaints and investigates alleged breaches of the Code of Business Conduct and Ethics.
2
A clawback policy is in place to recover incentive-based executive compensation in the event of a financial restatement.
3
The Board of Directors has affirmatively determined that six of its seven directors are independent, resulting in approximately 85.7% independent directors.
4
The company has a Code of Business Conduct and Ethics that promotes compliance with anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, and references PhRMA and OIG guidelines, but there is no information on training frequency or effectiveness metrics.
5
Kind to Animals
0
No evidence available to assess Tarsus Pharmaceuticals, Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Tarsus Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
Tarsus Pharmaceuticals, Inc. does not have publicly available data for any of the key environmental performance metrics.
1
Multiple articles explicitly state that there is no publicly available data for Scope 1, 2, and 3 emissions, SBTi-aligned targets, renewable energy percentage, water use, green building certifications, waste diversion, EU taxonomy alignment for capex, lifecycle impact analysis, recycled to virgin ratio, carbon offset quality, climate positive initiatives, supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policy implementation, environmental compliance violations, environmental impact assessments, net-zero target year, TCFD alignment, climate scenario analysis, stranded assets transparency, water from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing.
2
The company's Code of Conduct mentions adherence to environmental standards, but this is a policy statement, not evidence of specific performance or outcomes.
3
Respect for Cultures & Communities
0
No evidence available to assess Tarsus Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company's privacy notice outlines user rights under CCPA and Nevada law, allowing access, deletion, and opt-out of data sharing for behavioral advertising.
1
No incidents of unauthorized data use are documented.
2
Tarsus Pharmaceuticals conducts annual penetration testing and addresses compliance with regulations such as CCPA, CPRA, and HIPAA.
3
Zero Waste & Sustainable Products
0
No specific, quantitative data is available regarding Tarsus Pharmaceuticals, Inc.'s waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education.
1
While the company is classified as a Recycler by the EPA, no specific metrics or details on its waste management practices are provided.
2